182 related articles for article (PubMed ID: 20204306)
1. RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer.
Wang ZG; Fukazawa T; Nishikawa T; Watanabe N; Sakurama K; Motoki T; Hatakeyama S; Omori O; Ohara T; Tanabe S; Fujiwara Y; Takaoka M; Shirakawa Y; Yamatsuji T; Tanaka N; Naomoto Y
Oncol Rep; 2010 Apr; 23(4):1167-72. PubMed ID: 20204306
[TBL] [Abstract][Full Text] [Related]
2. TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells.
Wang ZG; Fukazawa T; Nishikawa T; Watanabe N; Sakurama K; Motoki T; Takaoka M; Hatakeyama S; Omori O; Ohara T; Tanabe S; Fujiwara Y; Shirakawa Y; Yamatsuji T; Tanaka N; Naomoto Y
Oncol Rep; 2008 Dec; 20(6):1473-7. PubMed ID: 19020730
[TBL] [Abstract][Full Text] [Related]
3. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
Grozinsky-Glasberg S; Rubinfeld H; Nordenberg Y; Gorshtein A; Praiss M; Kendler E; Feinmesser R; Grossman AB; Shimon I
Mol Cell Endocrinol; 2010 Feb; 315(1-2):87-94. PubMed ID: 19815051
[TBL] [Abstract][Full Text] [Related]
4. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
Grozinsky-Glasberg S; Franchi G; Teng M; Leontiou CA; Ribeiro de Oliveira A; Dalino P; Salahuddin N; Korbonits M; Grossman AB
Neuroendocrinology; 2008; 87(3):168-81. PubMed ID: 18025810
[TBL] [Abstract][Full Text] [Related]
5. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
[TBL] [Abstract][Full Text] [Related]
6. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease.
Zitzmann K; Rüden Jv; Brand S; Göke B; Lichtl J; Spöttl G; Auernhammer CJ
Cancer Lett; 2010 Sep; 295(1):100-9. PubMed ID: 20356670
[TBL] [Abstract][Full Text] [Related]
7. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
Boulay A; Rudloff J; Ye J; Zumstein-Mecker S; O'Reilly T; Evans DB; Chen S; Lane HA
Clin Cancer Res; 2005 Jul; 11(14):5319-28. PubMed ID: 16033851
[TBL] [Abstract][Full Text] [Related]
9. RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase.
Lee KH; Hur HS; Im SA; Lee J; Kim HP; Yoon YK; Han SW; Song SH; Oh DY; Kim TY; Bang YJ
Cancer Lett; 2010 Dec; 299(1):22-8. PubMed ID: 20727673
[TBL] [Abstract][Full Text] [Related]
10. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR.
Hou G; Xue L; Lu Z; Fan T; Tian F; Xue Y
Cancer Lett; 2007 Aug; 253(2):236-48. PubMed ID: 17360108
[TBL] [Abstract][Full Text] [Related]
11. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J
Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
[TBL] [Abstract][Full Text] [Related]
12. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001.
Loehberg CR; Strissel PL; Dittrich R; Strick R; Dittmer J; Dittmer A; Fabry B; Kalender WA; Koch T; Wachter DL; Groh N; Polier A; Brandt I; Lotz L; Hoffmann I; Koppitz F; Oeser S; Mueller A; Fasching PA; Lux MP; Beckmann MW; Schrauder MG
Biochem Pharmacol; 2012 Feb; 83(4):480-8. PubMed ID: 22142888
[TBL] [Abstract][Full Text] [Related]
13. Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids.
Zatelli MC; Minoia M; Martini C; Tagliati F; Ambrosio MR; Schiavon M; Buratto M; Calabrese F; Gentilin E; Cavallesco G; Berdondini L; Rea F; degli Uberti EC
Endocr Relat Cancer; 2010 Sep; 17(3):719-29. PubMed ID: 20554786
[TBL] [Abstract][Full Text] [Related]
14. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells.
Zitzmann K; De Toni EN; Brand S; Göke B; Meinecke J; Spöttl G; Meyer HH; Auernhammer CJ
Neuroendocrinology; 2007; 85(1):54-60. PubMed ID: 17310129
[TBL] [Abstract][Full Text] [Related]
15. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
16. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells.
Zakikhani M; Blouin MJ; Piura E; Pollak MN
Breast Cancer Res Treat; 2010 Aug; 123(1):271-9. PubMed ID: 20135346
[TBL] [Abstract][Full Text] [Related]
17. Enhanced radiation damage of tumor vasculature by mTOR inhibitors.
Shinohara ET; Cao C; Niermann K; Mu Y; Zeng F; Hallahan DE; Lu B
Oncogene; 2005 Aug; 24(35):5414-22. PubMed ID: 15940265
[TBL] [Abstract][Full Text] [Related]
18. [Effects of mTOR siRNA on mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cells and the growth of transplanted tumor in nude mice].
Liu MY; Hou GQ; Zhang Y; Bei WJ; Yan AH
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):334-9. PubMed ID: 21875460
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001.
Wedel S; Hudak L; Seibel JM; Juengel E; Tsaur I; Wiesner C; Haferkamp A; Blaheta RA
Life Sci; 2011 Feb; 88(9-10):418-24. PubMed ID: 21192952
[TBL] [Abstract][Full Text] [Related]
20. Acetaldehyde promotes rapamycin-dependent activation of p70(S6K) and glucose uptake despite inhibition of Akt and mTOR in dopaminergic SH-SY5Y human neuroblastoma cells.
Fang CX; Yang X; Sreejayan N; Ren J
Exp Neurol; 2007 Jan; 203(1):196-204. PubMed ID: 16962100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]